{
  "abstract": "Head and neck squamous cell carcinoma (HNSCC) is a malignancy with limited responses to immune checkpoint blockade, due to insufficient tumor immunogenicity and immunosuppressive signaling. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) has emerged to negatively regulate antitumor immune responses. However, effective tumor-targeted delivery of PTPN2 inhibitors remains a major challenge. Herein, we developed an anti-PD-L1 antibody-functionalized Mn metal-organic framework nanoplatform (Pi@MOF@aP). The manganese-based MOF core efficiently encapsulated the PTPN2 inhibitor and enabled pH-responsive release under the acidic tumor microenvironment. Surface modification with anti-PD-L1 antibodies enhanced tumor targeting, promoted selective cellular uptake, and provided additional immune checkpoint blockade. Pi@MOF@aP exhibited potent cytotoxicity against HNSCC cells while maintaining favorable compatibility with normal oral keratinocytes. Mechanistically, Pi@MOF@aP-mediated PTPN2 inhibition activated the cGAS-STING pathway, increased cytokine production, and enhanced antitumor immune responses. In HNSCC mouse models, Pi@MOF@aP achieved efficient tumor accumulation, significantly inhibited tumor growth, prolonged survival, and promoted CD4 + and CD8 + T cells` infiltration with no obvious toxicity. Therefore, this study presents a multifunctional nanotherapeutic platform that integrates targeted PTPN2 inhibition, PD-L1 blockade, and cGAS-STING activation, providing a promising strategy for improving immunotherapy efficacy in HNSCC.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurovascular Surgery, First Hospital of Jilin University, Changchun, Jilin, 130021, China",
    "Department of Thoracic Surgery II, Department of Lung Transplantation, Organ Transplantation Center, First Hospital of Jilin University, Changchun, Jilin, 130021, China",
    "Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China",
    "Department of Otolaryngology–Head and Neck Surgery, First Hospital of Jilin University, Changchun, Jilin, 130021, China; Corresponding author at: 1 Xinmin Street, Changchun, 130021, Jilin, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zhanpeng Zhu"
    },
    {
      "affs": [
        1
      ],
      "name": "Rui Wang"
    },
    {
      "affs": [
        2
      ],
      "name": "Wei Li"
    },
    {
      "affs": [
        3
      ],
      "name": "Yu Cui"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6v19mk9j83z6n.bib",
  "cited_by": 0,
  "doi": "10.1016/j.ijpx.2026.100694",
  "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S2590156726002148",
  "id": "6v19mk9j83z6n",
  "issns": [
    "2590-1567"
  ],
  "landing_url": "https://doi.org/10.1016/j.ijpx.2026.100694",
  "language": "en",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Paper"
    ],
    [
      "lcc",
      "RS1-441"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7223004092",
  "pdf_url": "https://europepmc.org/articles/PMC13715415?pdf=render",
  "pmcid": "PMC13715415",
  "pmid": "42953321",
  "published": "2026-10-20",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/6v19mk9j83z6n.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:44:38Z",
      "native_id": "ff056f1d93e444049c98d4f4f6e3460b",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.ijpx.2026.100694"
    },
    {
      "first_seen": "2026-10-31T00:20:41Z",
      "native_id": "MED:42953321",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42953321"
    },
    {
      "first_seen": "2026-11-01T12:22:43Z",
      "native_id": "PMC13715415",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.ijpx.2026.100694"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Anti-PD-L1 antibody-coated metal-organic framework for targeted PTPN2 Inhibitor delivery and enhanced immunotherapy of head and neck squamous cell carcinoma",
  "title_text": "Anti-PD-L1 antibody-coated metal-organic framework for targeted PTPN2 Inhibitor delivery and enhanced immunotherapy of head and neck squamous cell carcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:22:43Z",
  "url": "https://research.draconitic.com/paper/6v19mk9j83z6n",
  "venue": "International Journal of Pharmaceutics: X",
  "versions": []
}